These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 31345387)

  • 1. Standard of care vs reduced-dose chemoradiation after induction chemotherapy in HPV+ oropharyngeal carcinoma patients: The Quarterback trial.
    Misiukiewicz K; Gupta V; Miles BA; Bakst R; Genden E; Selkridge I; Surgeon JT; Rainey H; Camille N; Roy E; Zhang D; Ye F; Jia R; Moshier E; Bonomi M; Hwang M; Som P; Posner MR
    Oral Oncol; 2019 Aug; 95():170-177. PubMed ID: 31345387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality of Life Analysis of HPV-Positive Oropharyngeal Cancer Patients in a Randomized Trial of Reduced-Dose Versus Standard Chemoradiotherapy: 5-Year Follow-Up.
    Takahashi M; Hwang M; Misiukiewicz K; Gupta V; Miles BA; Bakst R; Genden E; Selkridge I; Botzler J; Virani V; Moshier E; Bonomi MR; Posner MR
    Front Oncol; 2022; 12():859992. PubMed ID: 35463348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of chemotherapy regimen on treatment outcomes in patients with HPV-associated oropharyngeal cancer with T4 disease treated with definitive concurrent chemoradiation.
    Bhattasali O; Ryoo JJ; Thompson LDR; Abdalla IA; Chen J; Iganej S
    Oral Oncol; 2019 Aug; 95():74-78. PubMed ID: 31345397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mature results of a prospective study of deintensified chemoradiotherapy for low-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma.
    Chera BS; Amdur RJ; Tepper JE; Tan X; Weiss J; Grilley-Olson JE; Hayes DN; Zanation A; Hackman TG; Patel S; Sheets N; Weissler MC; Mendenhall WM
    Cancer; 2018 Jun; 124(11):2347-2354. PubMed ID: 29579339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group.
    Marur S; Li S; Cmelak AJ; Gillison ML; Zhao WJ; Ferris RL; Westra WH; Gilbert J; Bauman JE; Wagner LI; Trevarthen DR; Balkrishna J; Murphy BA; Agrawal N; Colevas AD; Chung CH; Burtness B
    J Clin Oncol; 2017 Feb; 35(5):490-497. PubMed ID: 28029303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma.
    Haddad RI; Massarelli E; Lee JJ; Lin HY; Hutcheson K; Lewis J; Garden AS; Blumenschein GR; William WN; Pharaon RR; Tishler RB; Glisson BS; Pickering C; Gold KA; Johnson FM; Rabinowits G; Ginsberg LE; Williams MD; Myers J; Kies MS; Papadimitrakopoulou V
    Ann Oncol; 2019 Mar; 30(3):471-477. PubMed ID: 30596812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer.
    Seiwert TY; Foster CC; Blair EA; Karrison TG; Agrawal N; Melotek JM; Portugal L; Brisson RJ; Dekker A; Kochanny S; Gooi Z; Lingen MW; Villaflor VM; Ginat DT; Haraf DJ; Vokes EE
    Ann Oncol; 2019 Feb; 30(2):297-302. PubMed ID: 30481287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study.
    Chen AM; Felix C; Wang PC; Hsu S; Basehart V; Garst J; Beron P; Wong D; Rosove MH; Rao S; Melanson H; Kim E; Palmer D; Qi L; Kelly K; Steinberg ML; Kupelian PA; Daly ME
    Lancet Oncol; 2017 Jun; 18(6):803-811. PubMed ID: 28434660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.
    Gillison ML; Trotti AM; Harris J; Eisbruch A; Harari PM; Adelstein DJ; Jordan RCK; Zhao W; Sturgis EM; Burtness B; Ridge JA; Ringash J; Galvin J; Yao M; Koyfman SA; Blakaj DM; Razaq MA; Colevas AD; Beitler JJ; Jones CU; Dunlap NE; Seaward SA; Spencer S; Galloway TJ; Phan J; Dignam JJ; Le QT
    Lancet; 2019 Jan; 393(10166):40-50. PubMed ID: 30449625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic evaluation and meta-analysis of the prognosis of down-staging human papillomavirus (HPV) positive oropharyngeal squamous cell carcinoma using cetuximab combined with radiotherapy instead of cisplatin combined with radiotherapy.
    Hu Q; Li F; Yang K
    PeerJ; 2024; 12():e17391. PubMed ID: 38784388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of cisplatin dose and smoking pack-years in human papillomavirus-positive oropharyngeal squamous cell carcinoma treated with chemoradiotherapy.
    Oliva M; Huang SH; Xu W; Su J; Hansen AR; Bratman SV; Ringash J; Jang R; Cho J; Bayley A; Hope AJ; Chen E; Giuliani M; Waldron J; Weinreb I; Perez-Ordonez B; Chepeha D; Kim J; O Sullivan B; Siu LL; Spreafico A
    Eur J Cancer; 2019 Sep; 118():112-120. PubMed ID: 31330486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concurrent cisplatin or cetuximab with radiotherapy for HPV-positive oropharyngeal cancer: Medical resource use, costs, and quality-adjusted survival from the De-ESCALaTE HPV trial.
    Jones DA; Mistry P; Dalby M; Fulton-Lieuw T; Kong AH; Dunn J; Mehanna HM; Gray AM
    Eur J Cancer; 2020 Jan; 124():178-185. PubMed ID: 31794928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term outcomes of induction chemotherapy followed by chemoradiotherapy vs chemoradiotherapy alone as treatment of unresectable head and neck cancer: follow-up of the Spanish Head and Neck Cancer Group (TTCC) 2503 Trial.
    Hitt R; Iglesias L; López-Pousa A; Berrocal-Jaime A; Grau JJ; García-Girón C; Martínez-Trufero J; Guix M; Lambea-Sorrosal J; Del Barco-Morillo E; León-Vintró X; Cunquero-Tomas AJ; Baste N; Ocaña A; Cruz-Hernández JJ;
    Clin Transl Oncol; 2021 Apr; 23(4):764-772. PubMed ID: 32797376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Locoregional Recurrence in p16-Positive Oropharyngeal Squamous Cell Carcinoma After TORS.
    Carey RM; Brody RM; Shimunov D; Shinn JR; Mady LJ; Rajasekaran K; Cannady SB; Lin A; Lukens JN; Bauml JM; Cohen RB; Basu D; O'Malley BW; Weinstein GS; Newman JG
    Laryngoscope; 2021 Dec; 131(12):E2865-E2873. PubMed ID: 34076275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes after primary intensity-modulated radiation therapy for oropharyngeal squamous cell carcinoma at a New Zealand regional cancer centre: Impact of p16 status.
    Maqsood S; Jameson MB; De Groot C; Hartopeanu C; Yasin NABHM; Thotathil Z
    Cancer Rep (Hoboken); 2018 Jun; 1(1):e1001. PubMed ID: 32729235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective Treatment Deintensification by Reducing Radiation Dose and Omitting Concurrent Chemotherapy Based on Response to Induction Chemotherapy in Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma: A Single-Arm, Phase 2 Trial (IChoice-01).
    Xu T; Shen C; Zhou X; Zhu L; Xiang J; Wang Y; Zhu Y; He X; Ying H; Wang Y; Ji Q; Hu C; Lu X
    Int J Radiat Oncol Biol Phys; 2024 Jan; 118(1):169-178. PubMed ID: 37574169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Costs of Definitive Chemoradiation, Surgery, and Adjuvant Radiation Versus De-Escalated Adjuvant Radiation per MC1273 in HPV+ Cancer of the Oropharynx.
    Waddle MR; Ma DJ; Visscher SL; Borah BJ; May JM; Price KA; Moore EJ; Patel SH; Hinni ML; Chintakuntlawar AV; Garcia JJ; Graner DE; Neben-Wittich MA; Garces YI; Hallemeier CL; Price DL; Kasperbauer JL; Janus JR; Foote RL; Miller RC
    Int J Radiat Oncol Biol Phys; 2021 Jun; 110(2):396-402. PubMed ID: 33359567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiation Therapy Alone for Human Papillomavirus-Related Squamous Cell Carcinoma of the Oropharynx: A Single-Arm, Phase 2 Study.
    Takemoto N; Seo Y; Nakahara S; Yoshioka Y; Teshima T; Fujii T; Isohashi F; Otani K; Yoshii T; Takenaka Y; Suzuki M; Fukusumi T; Hanamoto A; Yasui T; Michiba T; Yamamoto Y; Shimamoto S; Tanaka H; Tatsumi M; Ogawa K; Inohara H
    Int J Radiat Oncol Biol Phys; 2021 Jun; 110(2):403-411. PubMed ID: 33373656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. De-Escalated Adjuvant Therapy After Transoral Robotic Surgery for Human Papillomavirus-Related Oropharyngeal Carcinoma: The Sinai Robotic Surgery (SIRS) Trial.
    Miles BA; Posner MR; Gupta V; Teng MS; Bakst RL; Yao M; Misiukiewicz KJ; Chai RL; Sharma S; Westra WH; Kim-Schulze S; Dayal B; Sobotka S; Sikora AG; Som PM; Genden EM
    Oncologist; 2021 Jun; 26(6):504-513. PubMed ID: 33675133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer.
    Seiwert TY; Melotek JM; Blair EA; Stenson KM; Salama JK; Witt ME; Brisson RJ; Chawla A; Dekker A; Lingen MW; Kocherginsky M; Villaflor VM; Cohen EE; Haraf DJ; Vokes EE
    Int J Radiat Oncol Biol Phys; 2016 Sep; 96(1):21-9. PubMed ID: 27511844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.